"CBD is Safe. Here’s the Data"
The US Hemp Roundtable, an organization we support that fights on our behalf for fair hemp laws & regulation, just made the above statement to the FDA in hopes of speeding up their ponderous deliberation on creating CBD product guidelines.
The statement was made along with a long letter (found below) to the FDA illustrating scientific evidence around the safety of CBD.
More on that in a moment.
Since the passing of the Farm Bill last year, ALL hemp products have become 100% legal.
Yet, here we are today waiting for the FDA to create some guidelines for products that contain CBD, a compound in a plant that's been demonstrated to be safe.
There absolutely needs to be an oversight on quality products entering the marketplace but sadly this is not the conversation being held at the moment.
This waiting game is making banks uneasy since these rules are not defined and that is the main reason we still have to wait to be able to process all major credit cards.
The synopsis of the letter is around what we in the industry and those of you taking our product already know:
It's safe and effective in low and high doses, there are many scientific studies and personal testimonials that further validate the necessity of CBD being widely available in the marketplace.
Summary of US Hemp Roundtable Recommendations To The FDA:
- CBD does not appear to pose unreasonable safety risks to consumers and therefore can be regulated by FDA like any other botanical ingredient used in these products. This position is supported by clinical studies conducted at dosages at or above what is commonly used in dietary supplements, food, and cosmetics. Several of these studies are in sensitive populations.
- Appropriate levels of CBD will be much lower in food and dietary ingredients than those used in pharmaceutical products. However, we advise against establishing arbitrary dose limits for these products as the effects of the CBD will vary greatly based on the intended use, formulation, and mode of delivery. Each manufacturer has the burden to establish its specific product formulation is safe for the intended population through FDA’s current regulatory framework.
- Safety concerns that may arise from the lack of data in vulnerable populations such as children, pregnant or lactating women, and patients taking therapeutic levels of CBD can be addressed in the labeling of the product with adequate advisory language and directions for use.
- FDA’s current regulatory system supports incentives for drug development, and clearly and sufficiently distinguishes these products from food and dietary ingredients based on their intended use and labeling.
The full letter is below: